Type of work: peer-reviewed/clinical trial/people A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression. This industry-funded work is presented for the first time at the 36th ECNP Congress in Barcelona, with publication in the peer-reviewed journal the New England Journal of Medicine (see Notes for details) . Clinical depression (also known as MDD, major depressive disorder) affects a significant number of people at any one time, giving them real life problems and increasing the health-related costs.

https://www.miragenews.com/ketamine-derived-drug-enhances-hard-to-treat-1097487/

#miragenews